- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03626246
Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Kidney disease patients have abnormal protein (bone collagen) modifications in their bone that may increase the risk of breaking a bone (fracture). Preventing bone collagen from becoming abnormal may decrease the risk of breaking a bone, such as the spine or hip. Currently, the effect of abnormal bone collagen on bone strength is not fully defined, and there are no methods to measure the abnormal protein content without a bone biopsy. The purpose of this study is to define the effects of bone collagen on bone strength and to identify non-invasive markers that will tell us how much abnormal collagen is in the bone. If the investigators are able to identify a non-invasive marker of abnormal bone protein then they may be able to prevent the build-up of this protein and lower the risk of a fracture.
If the participant chooses to be in the study, the investigators will get information from the participant's medical records such as diagnosis, the medicines and treatments prescribed by the participant's doctor, and the participant's lab test results.
There will be two study visits, each lasting about 3 hours.
Visit 1: At the baseline visit, study procedures include:
- Completing medical history, physical activity level, and dietary questionnaires for calcium and vitamin D.
- Blood sample
- Bone Imaging will: dual energy X-ray absorptiometry (DXA) to measure bone mineral density, high-resolution peripheral quantitative computed tomography (HRpQCT) to measure bone quality, and back x-rays to assess for the presence of spine fractures.Females who are able to become pregnant will also provide a urine specimen for pregnancy testing. (A negative pregnancy test is required prior to bone imaging.)
- Measure levels of Advanced Glycation End products (AGEs) in the skin of the participant's forearm and also in the participant's bone by bone biopsy. Advance Glycation End products may play a role in the development of weakened bone due to chronic kidney disease.
Visit 2: The participant's second visit will occur within 6-months of enrollment. At this visit, the participant will undergo a bone and muscle biopsy at the hip area under conscious sedation and a localized pain numbing medicine. The bone biopsy provides detailed information about the quality of the participant's bone that cannot be obtained through other tests like x-rays or blood tests. The investigators will use the bone biopsy to determine the amount of abnormal protein in the participant's bone. The muscle biopsy informs about the health of the participant's muscle fibers and allows us to detect any muscle mass wasting associated to chronic kidney disease. Since the piece of muscle is taken form the bone biopsy, no extra incision is needed.
The duration of the participant's participation from start of antibiotics through the actual bone biopsy will be approximately 3 weeks and 5 days (26 days).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia/CUMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Chronic kidney disease stage 3, 4 or 5
- Stable dose of vitamin D for 2-months
Exclusion Criteria:
- Dialysis
- Current use or treatment in the past one year with oral or inhaled glucocorticoids for more than 90 days.
- Current use or treatment in the past one year with sex hormone/SERM therapy for more than 30 days.
- Any use of bisphosphonates.
- Use of anti-osteoporosis therapies (denosumab, teriparatide, calcitonin or anti-sclerostin antibodies) in last 2 years.
- Any solid organ transplant or bone marrow transplant (Not including skin or cornea).
- Patients on non-aspirin anticoagulants that cannot be reasonably held for biopsy.
- Any cancers within 5-yrs of diagnosis that were metastatic to bone, and that are not in complete remission
- Any history of leukemia, multiple myeloma, lymphoma, amyloid or paraproteinemias.
- Any congenital or acquired collagen of bone diseases other than osteoporosis or renal osteodystrophy (Including but not limited to: Osteogenesis Imperfecta, X-Linked Hypophosphatemic Rickets, Pagets or Cushings Disease).
- History of Primary Hyperparathyroidism within 2-years of Parathyroidectomy.
- Hypoparathyroidism - primary or post-surgical
- Hyperthyroidism - if untreated and not on stable dose of medication for 6 months
- Hypothyroidism - if untreated and not on stable dose of medication for 6 months
- Non-ambulatory
- Bilateral lower extremity amputations.
- Weight >300 lbs.
- Medical disease - end stage heart, end stage liver, celiac disease and other intestinal malabsorption
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Kidney disease
Patients who participate in our study are 40 years old or older and have a Chronic kidney disease stage 3, 4 or 5.
|
Being part of this study you agree to participate in all these interventions: Genetic: • Blood sample Procedure/Surgery: • Bone and muscle biopsies. Radiation:
Other:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine amounts of abnormal collagen present in the bone of CKD patients
Time Frame: 2.5 years
|
In patients with CKD stage 3-5, the investigators will obtain transiliac crest bone biopsies and determine the amount of advanced glycation end-products that are present in bone collagen
|
2.5 years
|
Determine if greater amounts of abnormal collagen in the bone of CKD patients decreases bone strength
Time Frame: 1 year
|
In patients with CKD stage 3-5, the investigators will perform biomechanical testing of bone biopsy specimens and determine if greater degree of advanced glycation end-product modification of bone collagen changes bone strength.
|
1 year
|
To identify non-invasive biomarkers of advanced glycation end-products in bone collagen
Time Frame: 1 year
|
In patients with CKD stage 3-5, to obtain blood and skeletal imaging with high resolution peripheral computed tomography and to determine if the concentration of advanced glycation end-products in bone collagen can be identified by non-invasive methods.
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas Nickolas, MD,MS, Columbia University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Urologic Diseases
- Endocrine System Diseases
- Renal Insufficiency
- Nutrition Disorders
- Musculoskeletal Diseases
- Parathyroid Diseases
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Bone Diseases, Metabolic
- Calcium Metabolism Disorders
- Rickets
- Vitamin D Deficiency
- Kidney Diseases
- Renal Insufficiency, Chronic
- Hyperparathyroidism
- Kidney Failure, Chronic
- Bone Diseases
- Hyperparathyroidism, Secondary
- Chronic Kidney Disease-Mineral and Bone Disorder
Other Study ID Numbers
- AAAQ7778
- 1R01DK110871-01 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
Clinical Trials on Kidney disease
-
Hospital Civil Juan I. MenchacaNot yet recruitingMalnutrition | Peritoneal Dialysis | Oxidative Stress | Protein-Energy Malnutrition | Protein-Energy Wasting | Oral Nutritional Supplements
-
University of ManitobaBoehringer Ingelheim; Research Manitoba; First Nations Health and Social Secretariat... and other collaboratorsNot yet recruitingKidney Disease, Chronic
-
University of Alabama at BirminghamNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not yet recruitingChronic Kidney Disease | Decision Making, Shared | Family Caregiving
-
Centre Hospitalier Universitaire de NīmesCompletedChronic Kidney Diseases | Acute Kidney InjuryFrance
-
Alexandria UniversityRecruitingChronic Kidney Diseases | Urinary Tract InfectionsEgypt
-
University of Illinois at ChicagoPatient-Centered Outcomes Research InstituteCompleted
-
University of Alabama at BirminghamRecruitingKidney Diseases | Cardiometabolic Risk FactorsUnited States
-
VA Office of Research and DevelopmentRecruitingHemodialysis | Peritoneal Dialysis | End Stage Renal Disease | Chronic Kidney DiseaseUnited States
-
The Second Hospital of Nanjing Medical UniversityRecruiting
-
Assiut UniversityNot yet recruitingChronic Kidney Diseases | Manifestation, Skin